CRIS Current Research Information System

GHELLI LUSERNA DI RORÀ, ANDREA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.856
AS - Asia 2.381
EU - Europa 2.117
AF - Africa 185
SA - Sud America 98
OC - Oceania 7
Continente sconosciuto - Info sul continente non disponibili 4
Totale 7.648
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.815
SG - Singapore 696
CN - Cina 634
VN - Vietnam 591
GB - Regno Unito 560
DE - Germania 278
SE - Svezia 274
IT - Italia 267
HK - Hong Kong 189
IN - India 125
NL - Olanda 119
RU - Federazione Russa 105
FR - Francia 94
CH - Svizzera 84
IE - Irlanda 77
BR - Brasile 67
FI - Finlandia 57
CI - Costa d'Avorio 48
TG - Togo 46
EE - Estonia 45
ZA - Sudafrica 44
KR - Corea 43
BE - Belgio 39
BG - Bulgaria 35
NG - Nigeria 33
CA - Canada 30
UA - Ucraina 26
JO - Giordania 21
JP - Giappone 19
ES - Italia 15
AR - Argentina 14
PL - Polonia 11
SC - Seychelles 11
AT - Austria 10
ID - Indonesia 9
UZ - Uzbekistan 9
IR - Iran 8
MX - Messico 8
BD - Bangladesh 6
GR - Grecia 6
AU - Australia 5
TR - Turchia 5
AE - Emirati Arabi Uniti 4
CL - Cile 4
EC - Ecuador 4
EU - Europa 4
LB - Libano 3
MK - Macedonia 3
PE - Perù 3
PK - Pakistan 3
PY - Paraguay 3
CZ - Repubblica Ceca 2
IL - Israele 2
KZ - Kazakistan 2
LT - Lituania 2
LV - Lettonia 2
NZ - Nuova Zelanda 2
SA - Arabia Saudita 2
TM - Turkmenistan 2
AL - Albania 1
CO - Colombia 1
CY - Cipro 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
GE - Georgia 1
GY - Guiana 1
HR - Croazia 1
IQ - Iraq 1
LA - Repubblica Popolare Democratica del Laos 1
LK - Sri Lanka 1
LU - Lussemburgo 1
MA - Marocco 1
MY - Malesia 1
NI - Nicaragua 1
NP - Nepal 1
PA - Panama 1
RO - Romania 1
RS - Serbia 1
SK - Slovacchia (Repubblica Slovacca) 1
SN - Senegal 1
TW - Taiwan 1
VE - Venezuela 1
Totale 7.648
Salva come PNG Salva come JPEG
Città #
Southend 509
Singapore 472
Ashburn 345
Chandler 335
Dong Ket 325
Fairfield 236
Hong Kong 189
Ann Arbor 164
Houston 127
Wilmington 123
Seattle 119
Woodbridge 119
Beijing 118
Cambridge 93
Hefei 93
Princeton 88
Boardman 86
Dublin 77
Bern 76
Santa Clara 74
Bologna 55
Abidjan 48
Lomé 46
Nanjing 46
New York 46
Westminster 44
Seoul 43
Padova 41
Brussels 38
Sofia 35
Munich 34
Medford 33
Helsinki 32
Los Angeles 32
Dallas 28
Hanoi 27
Berlin 26
Falls Church 26
Ho Chi Minh City 26
Abeokuta 25
Buffalo 24
Jinan 24
Redondo Beach 24
Amman 21
Redwood City 21
Bremen 19
Saint Petersburg 19
Turku 19
Nanchang 18
Frankfurt am Main 17
Toronto 17
Shenyang 16
Tokyo 16
Hebei 14
Changsha 13
Jiaxing 13
London 13
Milan 13
Shanghai 13
Hyderabad 12
Guangzhou 11
Paris 11
Mountain View 10
Redmond 10
San Diego 10
Brooklyn 9
Falkenstein 9
Phoenix 9
Turin 9
Zhengzhou 9
Hangzhou 8
Norwalk 8
Vienna 8
Bengaluru 7
Düsseldorf 7
Florence 7
Haiphong 7
Montreal 7
Salamanca 7
São Paulo 7
Warsaw 7
Chennai 6
Chicago 6
Manchester 6
San Francisco 6
Tianjin 6
Verona 6
Amsterdam 5
Augusta 5
Baoding 5
Biên Hòa 5
Chengdu 5
Jakarta 5
Kunming 5
Lappeenranta 5
Monmouth Junction 5
Ningbo 5
Orem 5
Pune 5
San Jose 5
Totale 5.123
Salva come PNG Salva come JPEG
Nome #
Adult "Triple Negative" ACUTE Lymphoblastic Leukemia Genome Wide Characterization 278
Chromothripsis in acute myeloid leukemia: Biological features and impact on survival 242
Blinatumomab Is Safe and Effective in Relapsed and MRD Positive B-ALL CD19+ Patients: The Bologna Compassionate Program Experience 222
Alterations in Pathways Regulating Phosphatidil Inositol 3 Phosphate (PI3P) Produce Both Cell Proliferation and Therapy Resistance, and Define a Group of Patients with Poor Prognosis in Acute Myeloid Leukemia (AML) 218
The alteration in key regulator genes of autophagy is mainstream mechanism of therapy resistance and impact prognosis of acute myelogenous leukemia (AML): results from diagnosis genomic analysis on 148 consecutive patients treated with intensive chemotherapy and long-term survival follow-up 215
Co-occurrence of alterations in the DNA damage repair genes synergize with uncontrolled proliferation and associate with very-poor prognosis in acute myeloid leukemia patients 210
Chromothripsis in Acute Myeloid Leukemia Is Strongly Associated with Poor Prognosis and TP53 Alterations 206
Targeting WEE1 to enhance conventional therapies for acute lymphoblastic leukemia 185
Clustering Adult ACUTE Lymphoblastic Leukemia (ALL) Philadelphia Negative (Ph-) By Whole Exome Sequencing (WES) Analysis 182
In vitro and in vivo single-agent efficacy of checkpoint kinase inhibition in acute lymphoblastic leukemia 182
Constitutive activation of the DNA damage response pathway as a novel therapeutic target in diffuse large B-cell lymphoma 174
Targeting the p53-MDM2 interaction by the small-molecule MDM2 antagonist Nutlin-3a: A new challenged target therapy in adult Philadelphia positive acute lymphoblastic leukemia patients 173
Inhibition of Checkpoint Kinase 1 (Chk1) and 2 (Chk2) is a novel therapeutic strategy in B- and T-Acute Lymphoblastic Leukemia (ALL). 171
Copy number variants signature in two patients with relapsed acute promyelocytic leukemia 169
Distinct pattern of alterations in tp53 mutated and wild type acute myeloid leukemia (AML) patients 169
Deficient necroptosis pathway as a negative prognostic factor in acute myeloid leukemia. 169
Immunosuppressive Treg cells acquire the phenotype of effector-T cells in chronic lymphocytic leukemia patients 168
Impact on survival of catastrophic karyotype events in 101 consecutive acute myeloid leukemia (AML) patients: High risk karyotype and chromothripsis 162
In vitro and in vivo single-agent efficacy of checkpoint kinase inhibition in acute lymphoblastic leukemia 160
Clec12a: A new AML stem cell-associated antigen 158
Prexasertib, a Chk1/Chk2 inhibitor, increases the effectiveness of conventional therapy in B-/T- cell progenitor acute lymphoblastic leukemia 156
DEEP MOLECULAR CHARACTERIZATION OF ADULT B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (BC-ALL) NEGATIVE FOR RECURRENT FUSION GENES REVEALS A HIGH COMPLEX GENETIC HETEROGENEITY INFLUENCING PROGNOSIS 155
Survival analysis of patients carrying different FLT3 mutations (internal tandem duplication (ITD) and tyrosine kinase domain (TKD) mutations) in 459 consecutive non M3 newly diagnosed acute myeloid leukemia (AML) 154
MHC-I Antigen Presentation Role in Immune Escape of Acute Myeloid Leukemia with High Burden of Genomic Aberration 154
The cell cycle checkpoint inhibitors in the treatment of leukemias 152
Microarray analysis to identifiy novel copy number alterations in acute myeloid leukemia 152
Survival and outcome data observed in 98 patients affected by acute myeloid leukemia undergoing chemotherapy consolidation courses treatment followed by autologous bone marrow transplantation (auto-BMT) 151
The synergistic efficacy of Chk1/Chk2 inhibitors and doxorubicin in the treatment of acute lymphoblastic leukemia 148
Ponatinib Is Well Tolerated and Active In Patients With Relapsed/Refractory Philadelphia Positive Acute Lymphoblastic Leukemia (PH+ ALL) and Advanced Phase Of Chronic Myelogenous Leukemia (CML) Harbouring T315I Mutation: The Bologna Experience 146
Enhance the Efficacy of Doxorubicin Destabilizing the G2/M Checkpoint with a CHK1/CHK2 Inhibitor Pre-Treatment on Acute Lymphoblastic Leukemia 145
Prognostic significance of alterations of pathways regulating autophagy in acute myeloid leukemia 145
Exploring the role of PARP1 inhibition in enhancing antibody–drug conjugate therapy for acute leukemias: insights from DNA damage response pathway interactions 132
Override the doxorubicin-induced G2/M checkpoint using cell-cycle checkpoint inhibitors on acute lymphoblastic leukemia 131
The Inhibition of Checkpoint Kinase 1 As a Promising Strategy to Increase the Effectiveness of Different Treatments in Acute Lymphoblastic Leukemia 130
Integrated genomic-metabolic classification of acute myeloid leukemia defines a subgroup with NPM1 and cohesin/DNA damage mutations 128
You have accessAlterations in Pathways Regulating Phosphatidil Inositol 3 Phosphate (PI3P) Produce Both Cell Proliferation and Therapy Resistance, and Define a Group of Patients with Poor Prognosis in Acute Myeloid Leukemia (AML) 127
ETV6::ABL1-Positive Myeloid Neoplasm: A Case of a Durable Response to Imatinib Mesylate without Additional or Previous Treatment 124
Pixantrone induces cell death through mitotic perturbations and subsequent aberrant cell divisions 124
Uncovering the expression of circPVT1 in the extracellular vesicles of acute myeloid leukemia patients 124
Specific chromosomic alterations confer therapy resistance in a cohort of 49 patients with newly diagnosed acute myeloid leukemia treated with intensive chemotherapy 121
DEREGULATED EXPRESSION OF CHECKPOINT KINASE 1 (CHK1) IN BCR-ABL-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (BCR-ABL+ ALL) SUGGESTS A NEW THERAPEUTIC TARGET 119
You have accessMine the Stability of the G2/M Checkpoint to Break Down Acute Lymphoblastic Leukemia Defenses Against Antineoplastic Drugs 119
Ponatinib is well tolerated and active in patients with relapsed/refractory philadelphia positive leukemias: The Bologna experience 118
The combination of the PARP inhibitor rucaparib and 5FU is an effective strategy for treating acute leukemias 109
New JAK2 heterozygous loss: A role in overall survival in acute myeloid leukemia patients 107
SINGLE-AGENT INHIBITION OF CHECKPOINT KINASE 1 (CHK1) AND 2 (CHK2) BY PF-0477736 (PFIZER) AS A NEW PROMISING THERAPY IN B-ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) 105
Therapeutic Targeting of Acute Myeloid Leukemia by Gemtuzumab Ozogamicin 100
Targeting PARP proteins in acute leukemia: DNA damage response inhibition and therapeutic strategies 98
The Wee1 Inhibitor, MK-1775, Sensitizes Leukemic Cells to Different Antineoplastic Drugs Interfering with DNA Damage Response Pathway 93
null 75
Therapeutic implications of intratumor heterogeneity for TP53 mutational status in Burkitt lymphoma 62
Pharmacological Inhibition of WIP1 Sensitizes Acute Myeloid Leukemia Cells to the MDM2 Inhibitor Nutlin-3a 61
Rearrangements of ATP5L‐KMT2A in acute lymphoblastic leukaemia 52
Totale 7.830
Salva come PNG Salva come JPEG
Categoria #
all - tutte 21.231
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 21.231
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021733 0 0 0 0 0 24 14 55 80 13 52 495
2021/2022972 108 34 55 82 97 55 22 47 40 61 188 183
2022/20231.248 148 170 66 173 99 87 30 55 186 34 82 118
2023/2024376 12 46 27 42 23 80 18 41 21 15 19 32
2024/20251.279 38 172 101 92 114 52 148 66 6 151 61 278
2025/20261.416 293 213 215 221 335 139 0 0 0 0 0 0
Totale 7.830